Solventum Corporation (SOLV)
| Market Cap | 12.71B +11.5% |
| Revenue (ttm) | 8.26B -0.6% |
| Net Income | 1.43B +277.8% |
| EPS | 8.16 +275.1% |
| Shares Out | 173.17M |
| PE Ratio | 8.99 |
| Forward PE | 10.93 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,681,960 |
| Open | 71.86 |
| Previous Close | 71.65 |
| Day's Range | 71.50 - 73.40 |
| 52-Week Range | 62.38 - 88.20 |
| Beta | 0.65 |
| Analysts | Buy |
| Price Target | 85.27 (+16.2%) |
| Earnings Date | May 5, 2026 |
About SOLV
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tap... [Read more]
Financial Performance
In 2025, Solventum's revenue was $8.33 billion, an increase of 0.86% compared to the previous year's $8.25 billion. Earnings were $1.56 billion, an increase of 224.84%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for SOLV stock is "Buy." The 12-month stock price target is $85.27, which is an increase of 16.20% from the latest price.
News
Solventum to Participate in the 2026 BofA Securities Health Care Conference
ST. PAUL, Minn., May 7, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the BofA Securities Health Care Conference on Wednesday, May ...
Solventum price target raised to $93 from $92 at KeyBanc
KeyBanc analyst Brett Fishbin raised the firm’s price target on Solventum (SOLV) to $93 from $92 and keeps an Overweight rating on the shares. While there continues to be noise
Solventum price target lowered to $90 from $105 at Stifel
Stifel lowered the firm’s price target on Solventum (SOLV) to $90 from $105 and keeps a Buy rating on the shares.
Solventum price target lowered to $78 from $82 at UBS
UBS analyst Kevin Caliendo lowered the firm’s price target on Solventum (SOLV) to $78 from $82 and keeps a Neutral rating on the shares.
Solventum forecasts annual profit at higher end on wound care demand
Medical device maker Solventum said on Tuesday it expects annual profit to be at the higher end of its previous forecast range, primarily driven by strong demand for its wound care and sterilization...
Solventum Earnings Call Transcript: Q1 2026
Q1 fiscal 2026 results exceeded expectations with strong organic growth, margin expansion, and EPS outperformance. Transformation initiatives, portfolio optimization, and new product launches are fueling momentum, while guidance for the year is maintained with EPS now expected at the high end of the range.
Solventum Reports First Quarter 2026 Financial Results
Reported sales decreased (3.0)%; organic sales increased 2.1% Affirms full-year 2026 organic sales growth and free cash flow guidance; estimates adjusted EPS will be toward the high end of existing ra...
Peltz's Trian urges Solventum to rightsize costs, divest non-core businesses
Nelson Peltz's Trian Fund Management on Thursday called on Solventum to rightsize overhead costs, divest non-core businesses and improve capital allocation in its latest appeal for a performance tur...
Trian sends letter to Solventum board, seeking changes, CNBC reports
Trian’s letter urges Solventum (SOLV) to separate its businesses, CNBC reports.
Solventum shares up 2.6% after CNBC says Trian sends letter to board
12:06 EDT Solventum (SOLV) shares up 2.6% after CNBC says Trian sends letter to board
Trian calls on Solventum board to ‘drive value creation’
Trian Fund Management, which beneficially owns nearly 5% of Solventum (SOLV) Corporation’s common stock and is one of the company’s largest active shareholders, published an open letter to the Solvent...
Trian Calls on Solventum's Board to Create Value; Publishes Open Letter and Slide Deck
Solventum's Spin-Out from 3M has Maximized Executive Compensation, Not Shareholder Value Outlines Three Initiatives to Improve Performance and Drive Value Creation at Solventum NEW YORK, April 30, 202...
Solventum price target lowered to $92 from $99 at KeyBanc
KeyBanc analyst Brett Fishbin lowered the firm’s price target on Solventum (SOLV) to $92 from $99 to reflect lower peer multiples, while keeping an Overweight rating on the shares. The
Solventum price target lowered to $92 from $98 at Piper Sandler
Piper Sandler lowered the firm’s price target on Solventum (SOLV) to $92 from $98 and keeps an Overweight rating on the shares. The firm is making only minor changes to
Solventum to Report First Quarter Fiscal 2026 Earnings on May 5, 2026
ST. PAUL, Minn., April 14, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its first quarter fiscal 2026 financial results on Tuesday, May 5, 2026, after the U.S. financial markets close.
Solventum price target lowered to $89 from $100 at BTIG
BTIG analyst Ryan Zimmerman lowered the firm’s price target on Solventum (SOLV) to $89 from $100 and keeps a Buy rating on the shares as part of a broader research
Solventum initiated with a Sell at Rothschild & Co Redburn
Rothschild & Co Redburn initiated coverage of Solventum (SOLV) with a Sell rating and $60 price target The firm believes the company will struggle to accelerate organic growth given its
Solventum Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Management outlined progress in transformation, with Separation halfway complete and full completion targeted by end of 2026. 2025 exceeded growth expectations, and 2026 guidance targets 2%-3% revenue growth and margin expansion despite tariff headwinds. Innovation and operational efficiency remain key drivers.
Solventum assumed with an Equal Weight at Wells Fargo
Wells Fargo analyst Larry Biegelsen assumed coverage of Solventum (SOLV) with an Equal Weight rating and $83 price target The firm is maintaining the current rating, price target and estimates.
Solventum to Participate in the 2026 KeyBanc Healthcare Forum
ST. PAUL, Minn., March 11, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a virtual fireside chat at the KeyBanc Healthcare Forum on Wednesday, Mar. 18...
Solventum price target raised to $82 from $79 at UBS
UBS analyst Kevin Caliendo raised the firm’s price target on Solventum (SOLV) to $82 from $79 and keeps a Neutral rating on the shares. The firm updated its model following
Solventum price target raised to $99 from $97 at KeyBanc
KeyBanc raised the firm’s price target on Solventum (SOLV) to $99 from $97 and keeps an Overweight rating on the shares following quarterly results. The firm believes investors will view
Solventum beats quarterly estimates on strong demand for surgical products
Medical device maker Solventum on Thursday beat Wall Street estimates for the fourth quarter, helped by strong demand for its wound care and sterilization products.
Solventum Earnings Call Transcript: Q4 2025
Delivered strong Q4 and full-year 2025 results, with 3.3% organic sales growth and margin expansion despite headwinds from tariffs and separation costs. 2026 guidance calls for 2%-3% organic growth, margin improvement, and continued portfolio optimization, supported by new product launches and cost-saving initiatives.
Solventum sees 2026 adjusted EPS $6.40-$6.60, consensus $6.34
Sees 2026 organic revenue growth 2%-3% from $8.33B in 2025, consensus $8.02B.